In the field of metabolic disease treatment, new multi-target drugs are gradually overcoming the limitations of traditional single-target therapies. Tirzepatide (trade name Mounjaro/Zepbound), as the world's first approved dual receptor agonist of GLP-1 and GIP, has demonstrated significant efficacy in the treatment of diabetes and obesity; while Retatrutide (LY-3437943), a triple receptor agonist (GLP-1/GIP/GCGR) developed by Eli Lilly, although not yet on the market, its clinical data have attracted widespread attention. This article will deeply analyze the similarities and differences between these two drugs from five dimensions: mechanism of action, clinical efficacy, safety, target population, and market prospects.
|
|
|
|
|
|
|
|
Mechanism of Action: The Essential Differences between Dual-Target and Triple-Target Approaches
Tirzepatide achieves a "two-pronged" regulatory effect by simultaneously activating the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Activation of the GLP-1 receptor delays gastric emptying, suppresses appetite, and promotes insulin secretion; activation of the GIP receptor further enhances insulin secretion and may reduce food intake through the central nervous system. This dual-action mechanism makes it superior to single GLP-1 receptor agonists in terms of blood sugar control and weight management.
Retatrutide takes this a step further by simultaneously activating the three receptors: GLP-1, GIP, and GCGR (glucagon receptor), forming a "triple regulatory network". Activation of GCGR can increase energy consumption, promote fat breakdown, and suppress appetite. The synergistic effect with GLP-1/GIP may lead to a more significant metabolic improvement. For instance, in animal experiments, Retatrutide significantly enhanced the basal metabolic rate by upregulating the activity of brown adipose tissue. This mechanism has not yet been clearly confirmed in Tirzepatide.
Clinical Efficacy: Direct Comparison of Weight Reduction and Metabolic Improvement
Weight Management
Retatrutide Demonstrates Breakthrough Potential
In the Phase II clinical trial for obese patients, the highest-dose group of Retatrutide (12mg) achieved an average weight reduction of 24.2% within 48 weeks, far exceeding the 18.2% achieved by Tirzepatide in the same trial (highest dose 15mg). More strikingly, more than one-third of the patients in the Retatrutide group experienced a weight reduction of over 25%, while this proportion was approximately 20% for Tirzepatide. This difference may be attributed to the additional energy consumption increase resulting from the activation of GCGR.
Blood Glucose Control: Tirzepatide Still Has an Advantage
In the treatment of diabetes, the hypoglycemic effect of Tirzepatide is more prominent. The III-stage SURPASS series of trials showed that the highest dose group could reduce glycated hemoglobin (HbA1c) by 2.3%, while Retatrutide showed a 1.9% reduction in HbA1c in the II-stage trial for diabetic patients. This might be related to the stronger affinity of Tirzepatide for the GIP receptor - the role of GIP in insulin secretion may be more crucial in diabetic patients.
Comprehensive Metabolic Improvement: Both Drugs Show Multi-Dimensional Benefits
Both drugs can significantly improve blood lipids, blood pressure, and liver fat content. Retatrutide is slightly superior to Tirzepatide in reducing triglycerides and low-density lipoprotein cholesterol (LDL-C), while Tirzepatide performs better in increasing high-density lipoprotein cholesterol (HDL-C). Additionally, Retatrutide shows stronger anti-inflammatory and anti-fibrotic effects in animal experiments for non-alcoholic steatohepatitis (NASH), but its clinical efficacy still needs to be verified.
Safety: Differences and Countermeasures in Side Effect Profiles
Gastrointestinal Reactions: Common Challenges of Dual Drugs
As a common feature of GLP-1 receptor agonist drugs, both drugs may cause gastrointestinal side effects such as nausea, vomiting, and diarrhea. The incidence of gastrointestinal events for Tirzepatide is approximately 40%-50%, while for Retatrutide, the rate was reported to be 60% in the II phase trial. However, most of these were mild to moderate and gradually alleviated as the treatment duration increased. This might be related to Retatrutide's stronger appetite suppression effect.
Risk of hypoglycemia: Caution is needed with Tirzepatide
Due to the potential enhancement of insulin secretion by GIP receptor activation, the risk of hypoglycemia with Tirzepatide is slightly higher when used in combination with sulfonylureas or insulin compared to Retatrutide. While the activation of GCGR by Retatrutide may partially counteract the risk of hypoglycemia by antagonizing the insulin effect, the clinical data is not yet sufficient to completely rule out this possibility.
Long-term Safety: Exploration in an Unknown Field
Retatrutide, by simultaneously activating GCGR, may theoretically increase heart rate, blood pressure, or cause muscle loss. However, no significant signals have been observed in current clinical trials. The long-term cardiovascular safety of Tirzepatide has been preliminarily verified through the SURPASS-CVOT trial (non-inferior to placebo), and the III phase trial of Retatrutide will focus on monitoring such events.
Targeted Population: Differentiated Choices in Precision Medicine
Obese Patients: Retatrutide or the "Ultimate Weapon"
For obese patients with a BMI of 30 kg/m² or higher, or 27 kg/m² or higher with complications, the weight reduction achieved by Retatrutide may make it the preferred option. This is particularly applicable to patients who have not responded well to traditional therapies (such as single-target GLP-1 drugs) or who have metabolic resistance.
Diabetic patients
Tirzepatide remains the main hypoglycemic agent
Tirzepatide has been approved for the treatment of type 2 diabetes. Its potent hypoglycemic effect and cardiovascular protection make it the preferred choice for diabetic patients with obesity or cardiovascular diseases. Although Retatrutide performed well in diabetes trials, its hypoglycemic indication needs to await the support of III-phase data for approval.
Special Populations: Need Individualized Evaluation
Patients with renal dysfunction: Tirzepatide does not require dose adjustment, while Retatrutide's safety in severe renal dysfunction has not been clarified.
Cardiovascular disease patients: Tirzepatide has proven cardiovascular safety, while Retatrutide requires further verification.
Elderly patients: Both need cautious use, especially as Retatrutide may increase the risk of muscle loss.
Market Prospects: New Landscape of Innovation Drug Competition
Tirzepatide: Leading Advantage and Market Penetration
As the first dual-target drug, Tirzepatide has been approved in multiple markets worldwide, with sales exceeding $5 billion in 2023. After expanding to obesity and obstructive sleep apnea (OSA) indications, its market potential has been further unleashed. Eli Lilly's disease spectrum layout of "diabetes-obesity-metabolic syndrome" has consolidated its leadership position in the field of metabolic diseases.
Retatrutide: Differentiated Competition of the Late Arriver
Although Retatrutide is projected to launch in 2027, its clinical data has already garnered significant attention. Should Phase III trials confirm the sustainability of its weight reduction and metabolic improvements, it could potentially disrupt the existing market landscape. Eli Lilly may further expand its competitive edge through a "dual-drug combination" strategy (e.g., Tirzepatide paired with Retatrutide), but must remain vigilant against the risk of cumulative side effects.
Payment System and Accessibility Challenges
The high costs of both (with the projected annual treatment cost of Retatrutide exceeding $10,000) may limit its widespread adoption in developing countries. Additionally, the coverage of medical insurance, patient compliance (requiring a weekly injection), and long-term safety data will be the key factors determining its market performance.
Conclusion
The Future Path of Dual-Target and Triple-Target Therapies
The competition between Tirzepatide and Retatrutide is essentially a paradigm shift in the treatment of metabolic diseases from "single-target regulation" to "multi-pathway integration". Tirzepatide, with its leading position and clear efficacy, has become the current standard treatment; while if Retatrutide can prove the safety and long-term benefits of its triple mechanisms, it may usher in the era of "superweight loss drugs". In the future, as more triple-target drugs (such as Masdupeptide, LY3502970) enter clinical trials, the treatment of metabolic diseases will become more precise and individualized, ultimately benefiting hundreds of millions of patients worldwide.